The cardiopulmonary bypass equipment market comprises heart-lung machines, oxygenators, blood pumps, and cannula. These systems are used to divert blood from the veins to the arteries during open-heart surgery, allowing the heart to be stopped and opened. They oxygenate and circulate the blood during surgery when the heart needs to be isolated from the circulatory system. The global cardiopulmonary bypass equipment market is driven by the growing elderly population who are more prone to cardiovascular diseases. With rising life expectancy, the number of people aged 60 years and older is increasing substantially. This aging populace undergoes more cardiac procedures which fuels the demand for cardiopulmonary bypass equipment.
The Global Cardiopulmonary Bypass Equipment Market is estimated to be valued at US$ 138.26 Mn in 2024 and is expected to exhibit a CAGR of 5.5% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the cardiopulmonary bypass equipment market are Dow, Henkel, BASF, Nordson, LORD Corporation. Dow has a strong position in the oxygenator segment while Henkel leads the blood pumps market. BASF provides cannula and tubing sets.
The growing geriatric population suffering from cardiovascular diseases is a major demand driver for cardiopulmonary bypass equipment. With rising life expectancy, the aging population undergoing cardiac procedures is increasing rapidly. This augments the market for heart-lung machines, oxygenators, blood pumps, and other CPB equipment.
Technological advancements are supporting the cardiopulmonary bypass equipment market growth. Developments like miniaturized equipment and enhanced affinity membrane oxygenators with better biocompatibility and gas transfer ability are witnessing increased adoption. Integrated cardiopulmonary bypass management solutions and user-friendly interfaces are also gaining popularity.
Market Trends
Minimally invasive techniques: Developments in minimally invasive cardiac surgery using miniaturized CPB equipment are gaining ground. This reduces surgical trauma, fastens recovery and improves cosmetic outcomes.
Membrane oxygenators: Advanced membrane oxygenators using novel affinity materials exhibiting more efficient gas transfer and less thrombogenicity arereplacing bubble oxygenators.
Market Opportunities
Emerging markets: Growth opportunities exist in developing Asian, African and Latin American nations where cardiovascular diseases are on the rise due to lifestyle changes and aging population.
Home healthcare: Cardiopulmonary support equipment for home use can potentially reduce hospital stay and healthcare costs. Companies may invest in developing user-friendly home CPB solutions.
The outbreak of COVID-19 has significantly impacted the growth of the Cardiopulmonary Bypass Equipment Market Growth globally. Due to lockdowns imposed worldwide during early 2020, elective surgeries were postponed to focus resources on treating COVID-19 patients. This resulted in a decline in demand for cardiopulmonary bypass equipment from hospitals and cardiac surgery centers. However, as lockdowns eased from mid-2020 and healthcare systems prepared for resuming normal services while adhering to safety protocols, demand started recovering. Now, the demand is steadily reaching pre-COVID levels as more surgeries are being performed.
Pre-COVID, the market was growing at a healthy pace due to the rising geriatric population suffering from cardiovascular diseases and increasing number of complex cardiac surgeries performed worldwide. The market was also driven by technological advancements leading to improved cardiopulmonary bypass systems. However, post-COVID, the market is expected to observe faster growth to make up for the initial losses during the peak period of the pandemic. Market players are also focusing on developing innovative portable bypass machines and disposable components to meet future demand and support healthcare systems better during crises.
Manufacturers will need to closely monitor the evolving COVID-19 situation and impacts to devise agile supply chain and manufacturing strategies. Strengthening online product support capabilities can aid continued customer services. Raising awareness about safety of cardiac treatments is important to boost patient confidence and drive demand back to pre-pandemic levels over the coming years.
North America represents the most lucrative regional market for cardiopulmonary bypass equipment in terms of value, owing to the high number of complex cardiac surgeries performed annually in countries like the United States. This can be attributed to the rising prevalence of cardiovascular diseases and growing geriatric population in the region. Additionally, advanced healthcare infrastructure and high healthcare spending have supported market growth in North America.
Asia Pacific is anticipated to demonstrate the fastest growth over the forecast period amongst all regions. This growth can be creditied to factors like growing medical tourism, rising healthcare investments by governments and constant development of healthcare facilities with latest technologies across developing countries in the region. Increasing incidence of lifestyle diseases and improving access to cardiac treatments are also propelling the APAC market for cardiopulmonary bypass equipment.
Asia Pacific is projected to emerge as the fastest growing regional market for cardiopulmonary bypass equipment globally during the forecast period. This rapid growth can be attributed to the large patient pool suffering from cardiovascular diseases in densely populated countries like India and China. Additionally, rising healthcare expenditures, improving reimbursement policies, and increasing focus of market players on expanding their presence in the region by establishing manufacturing and distribution partnerships with local players are fueling market growth. Steady economic development over the past decade in various APAC countries has enhanced the affordability of quality cardiac treatments for a larger population base. This, along with growing medical tourism, is expected to drive continued high demand for cardiopulmonary bypass equipment in Asia Pacific.
For more insights, read-https://www.newsstatix.com/cardiopulmonary-bypass-equipment-market-trends-size-and-share-analysis/
Reasons to Purchase Our Research Report:1.
Analyzing the outlook of the market with the recent trends and SWOT analysis2.
Market dynamics scenario, along with growth opportunities of the market in the years to come3.
Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspects4.
Regional and country-level analysis integrating the demand and supply forces that are influencing the growth of the market.5.
Market value (USD Million) and volume (Units Million) data for each segment and sub-segment6.
The global Cetirizine OTC Market research report, published by Value Market Research, is designed to offer various market framework such as market size, portion, trends, growth path, value and factors that impact the current market dynamics over the forecast period 2020-2027.
Most importantly, this report also provides the latest significant strategies adopted by major players along with their market share.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the cetirizine otc market include J & J, Major(R) Pharmaceuticals, Sanofi, APOTEX, Teva, Pl Developments, Perrigo, Mckesson, CVS Pharmacy, Perrigo, Novel Laboratories.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Cetirizine OTC Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/cetirizine-otc-market/download-sampleMarket DynamicsThe rising prevalence of histamine borne allergic diseases drives the global cetirizine OTC market.
It affects about 30-40% of the world population and has become one of the three critical conditions in the 21st century.
Histamine is a significant mediator in allergic diseases.
